Drug Search Results
More Filters [+]

Totrombopag

Alternative Names: totrombopag, lgd-4665, lgd4665, lgd 4665
Latest Update: 2024-04-19
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: TPO Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Totrombopag

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Purpura, Thrombocytopenic, Idiopathic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

L4665-03

P2

Completed

Purpura, Thrombocytopenic, Idiopathic

2009-05-01

Recent News Events